Federal regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb and AstraZeneca.

The Food and Drug Administration said it approved the drug Onglyza to reduce blood sugar levels in patients with type 2 diabetes, which affects 24 million people in the United States.